FDA Removes Black-Box Warnings From Three Estrogen Patches

On Oct. 30, 2026, the FDA approved removing black-box warnings on cardiovascular risk, breast cancer and probable dementia from three estradiol patches—Minivelle, Vivelle and Vivelle-Dot. Labels still mention those risks. The move follows Feb. 12, 2026 changes for six other menopausal hormone therapy products, bringing the total to nine since a November 2025 directive. Twenty-nine companies have submitted labeling proposals. HHS tied the action to an Oct. 19, 2026 executive order on women's health. Health Secretary Robert F. Kennedy Jr. called removing outdated boxed-warning statements a major victory for women's health under President Trump's leadership. Acting FDA Commissioner Kyle Diamantas said the agency is advancing up-to-date labeling and access to treatment. At a press briefing, Dorothy Fink said patch output has doubled over the past year; Sarah Ibrahim said the FDA expedited 10 manufacturing supplements this year. HHS urged women who cannot find their usual patch to ask a pharmacist or provider. The FDA has not called a shortage. Susan Reed told Contemporary OB/GYN she was glad the warnings were lifted but said the pendulum has swung from the far left to the far right and that careful shared decision-making is even more important, especially for women with a uterus. The Guardian reported the FDA held no advisory committee meeting before the October 30 action. The FDA is exploring over-the-counter availability for vaginal estrogen products.



